Seikagaku Announces Revision of Consolidated Financial Forecasts for the Fiscal 2017 ending March 2018

Seikagaku Corporation (Tokyo, Japan; "Seikagaku") announced today that it has revised the consolidated financial forecast for the fiscal 2017 that was disclosed on May 12, 2017 as follows based on results of operations thus far in the fiscal year.

1. Revision of consolidated financial forecasts for the fiscal 2017
(April 1, 2017 to March 31, 2018)

(Millions of yen)

	Net sales	Operating income	Ordinary income	Net income attributable to owners of parent	Net income per share (Yen)
Previous Forecast (A)	30,300	1,500	3,750	2,700	47.65
Revised Forecast (B)	30,100	1,400	5,250	3,800	67.13
Change (B - A)	(200)	(100)	1,500	1,100	—
Change (%)	(0.7)	(6.7)	40.0	40.7	—
Reference: Results for fiscal 2016	29,589	1,282	2,477	1,787	31.55

2. Reason for the revision

Net sales are projected to be slightly less than previous forecast, primarily as a result of lower sales of pharmaceutical products in Japan. Profit indicators will be mixed, however. Although a decline in revenues is causing operating income to be below forecast, ordinary income and net income attributable to owners of parent are projected to be greater than our previous forecast. This is because of non-operating income generated by royalties received.

The forecast of R&D expenses remains unchanged from the 8,350 million yen in our previous forecast.

<Cautionary Notes>
This press release contains forward-looking statements regarding future management strategies or performance forecasts. These descriptions are based on judgments derived from information that is currently available to Seikagaku and are subject to risk and uncertainty. Actual results and developments may differ significantly from these descriptions due to various factors. Information about pharmaceutical products or medical devices (including products currently in development) contained in this press release is not intended to constitute an advertisement or medical advice.

#######